Replies to post #528339 on NorthWest Biotherapeutics Inc (NWBO)

[vator]

UCLA is tied by the licensing agreement. Your argument is unrealistic.

[Fireman02360]

My guess is UCLA legal doesn't want her associated with NWBO for whatever reason.

Its your guess and its wrong, again. Surely UCLA would demand NW Bio have the below language removed if they felt this way. With an endless piggy-bank and legal resources at its disposal, it could happen with a simple phone call from the UCLA Legal Team. But guess what, that didn't happen and remains on NW Bios website along with Dr. LLs continued support and clinical work with DC Vax and NW Bio.



Our Prior Phase I/II DCVax-L Trials for GBM
We, together with our collaborator, Dr. Linda Liau, conducted two prior Phase I/II clinical trials at UCLA with DCVax-L for GBM brain cancer. Those trials consisted of 39 patients, including 20 patients with newly diagnosed GBM and 19 patients recurrent GBM and other gliomas. The newly diagnosed patients who received DCVax in addition to standard of care treatment typically did not have tumor recurrence for a median of approximately 2 years (more than triple the usual time with standard of care treatments), and they survived for a median of approximately 3 years (about 2½ times the usual period of survival with standard of care treatment).